Bajaj Healthcare enters into CDMO contract with UK/EU-based companies for 15 new APIs

Thane: Bajaj Healthcare has informed the exchanges that the Company has entered into a definitive contract development and manufacturing organisation (CDMO) contract with UK/EU-based companies for 15 new APIs. This is in addition to 15 molecules for which we entered the contract with UK/EU based clients on 27th February 2024.
The new CDMO pipeline has a mix of, off Patent Generic APIs as well as APIs which are still under patent.
Read also: Bajaj Healthcare enters highly regulated opiate processing business
Speaking at the occasion Anil Jain, Managing Director, Bajaj Healthcare Limited, said, “We are delighted to share this development which reinforces the capabilities that we are building in terms of cost-effective route of synthesis in our R&D and the expansion of manufacturing capabilities, mostly at our USFDA, EU and now TGA, Australia approved site located at Block No. 588, SavliKarachiya Road, At & Post: Gothada, Tal. Savli, Dist: Vadodara, Gujarat."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.